COLLATERAL DAMAGE BY THE VACCINE DENGVAXIA AGAISNT DENGUE IN PHILLIPINES. !!
DAÑO COLATERAL POR LA VACUNA DENGVAXIA CONTRA EL DENGUE EN FILIPINAS. !!
ENGLISH EDITORIAL:
=================
Hello friends of the network DERMAGIC EXPRESS brings you another impressive topic that has to do once more with the VACCINES: it is the SCANDAL IN THE PHILIPPINES FOR THE DENGVAXIA VACCINE AGAINST THE DENGUE. A relatively new vaccine on the market that was approved by the FDA in the year 2015 to combat this plague "DENGUE" and the first country to put it into practice was the PHILIPPINES, although it was also approved in other countries.
THE DENGUE virus is transmitted by mosquito Aedes Aegypus, Aedes Albopictus, Aedes. Polynesiensis and Aedes scutellaris. The virus crosses the placenta, but is not associated with birth defects, it is also transmitted by blood transfusions and organ transplants. Until the year 2.015 there was no vaccine against this plague spread throughout much of the planet until the DENGVAXIA VACCINE was approved, manufactured by the French Sanofi-Pasteur laboratory, developed in (Lyon).
Today I brought this topic which is a clear demonstration of why the population day after day REJECTS MORE AND MORE VACCINES, it is not about advertising campaigns, neither "VAXERS" or "ANTIVAXERS" as society calls them. These are scientific and clinically proven events that show the failure of THE LABORATORIES in this case SANOFI-PASTEUR, who recognized in the year 2.016, months after the release of the DENGVAXIA VACCINE, the collateral damage of the same, after having been placed in 800,000 school children in the PHILIPPINES AND 300,000, in BRAZIL.
The DENGUE VIRUS (DENV) as I told you is transmitted by the bite of the aforementioned mosquitoes, it is a virus TYPE: RNA virus, from the FAMILY: Flaviviridae; GENUS: Flavivirus; SPECIES: Dengue viruses, of which there are 5 serotypes. Classically, we talked about 4 serotypes, but later a 5th serotype was described. Each of these is capable of manifesting the entire spectrum of the disease.
Some scientists argue that some are more virulent than others, popularly speaking of a CLASSIC DENGUE, which has no HEMORRHAGIC manifestations, or mild and a HEMORRHAGIC DENGUE, with severe manifestations of bleeding that can cause the death of the patient.
Dengue is the most widespread mosquitoes-transmitted disease in the world, with almost 400 million people infected each year. There are four dengue viruses, or serotypes, (there is a 5th serotype), most infected people recover and become immune to the first serotype they had. In some cases, a subsequent infection with a different serotype can cause severe hemorrhagic fever, called HEMORRHAGIC DENGUE, which is estimated to cause 25,000 deaths each year.
This is what led the LABORATORIES to develop VACCINES against this plague, not only SANOFI-PASTEUR, there are other THREE (3) VACCINES on trial, of which I will not mention anything at the moment because they have not been approved by the FDA yet.
DENGVAXIA is a vaccine called chimeric tetravalent yellow fever vaccine (CYD-TYD), composed of 4 chimeras YELLOW FEVER virus (17D-DENV) which is capable of causing the development of antibodies against the DENGUE virus (DENGV), and protects against the 4 most common serotypes of dengue. In this principle the creation of this VACCINE was based, which according to the same laboratory was 10 years developing. The vaccine is administered in 3 doses.
In summary DENGVAXIA is produced from the YELLOW FEVER virus genetically designed to produce stimulation of the immune system to produce antibodies against the DENGUE virus.
The "scandal" began to uncover in February 2,106 after the PHILIPPINES vaccination program was already under way and a doctor (DR Halstead) warned in a scientific article that the vaccine could put people at risk if they had not had dengue previously. He said that "the problem was well known." This researcher and others pointed out that in a DENGVAXIA study published in 2.015 it seemed to CONFIRM the fears that the vaccine could be harmful for those who had no previous EXPOSURE to dengue, noting that the potential danger was in the immune response to the VACCINE. It was found that children under 9 years of age who had received DENGVAXIA and subsequently were infected with DENGUE were more likely to be HOSPITALIZED due to serious diseases than those who had not been vaccinated.
To summarize: healthy children vaccinated with DENGVAXIA, that is to say seronegative, are more prone to develop a MORE SEVERE DENGUE and OTHER DISEASES than children NOT vaccinated with DENGVAXIA (seronegative also) and who were then acquired DENGUE.
The finding originally led Sanofi to restrict Dengvaxia to children 9 years old and older; In BRAZIL, the government decided to limit this vaccination program to children over 15 years of age. And the World Health Organization (WHO) in 2.017 recommended only using the vaccine in places where the incidence of DENGUE is high.
The vaccine was approved for use in 2,016 as "PARTIALLY" EFFECTIVE "in 11 countries: Mexico, the Philippines, Indonesia, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Thailand and Singapore ... The scandal erupted in the PHILIPPINES where 800,000 thousand school children were vaccinated regardless of their serological status, which is the high point of this vaccine.The SEROLOGICAL STATUS of the vaccinated and not THE AGE.
When the problem came to "light", the Philippine Food and Drug Administration ordered Sanofi to stop its campaign and in October 2016 fined Sanofi and Watson, a pharmacy chain that had started its own promotion campaign, for violating the advertising laws.
On November 29, 2017 SANOFI decided to "UPDATE" the information provided to doctors and patients about the DENGVAXIA VACCINATION and its performance, based on the request made by the countries that acquired it and affirm that it provides protection against dengue, but As I told you previously, they AFFIRMED THAT CERTAINLY and quote:
"... Those who had not been previously infected with the dengue virus (seronegative), the analysis found that in the longer term, more cases of severe disease could occur after vaccination after a dengue infection .."
This fact "ignited" the alarms and there were social demonstrations in front of the PHILIPPINES 'Parliament and two (2) days later on DECEMBER 1, 2017, 2 and a half months ago - the Philippines suspends the immunization program against dengue after the French pharmaceutical giant Sanofi warned that its flagship vaccine, DENGVAXIA, had shown that it presented health risks in people who had not been previously infected.
By the time of the suspension, more than 740,000 schoo lchildren had been vaccinated with DENGVAXIA, without taking into account the serological status of the children and the panel that proposed the suspension expressed its concern about the "REVELATION" of Sanofi regarding the problem of its vaccine.
To close this case we can mention that a few days ago March 8, 2,018 the PHILIPPINES health department warns of an outbreak of MORTAL MEASLESL, as a sequel to the problem caused by DENGVAXIA, relatives, parents and teachers refuse to VACCINATE their children with proven vaccines such as the SARAMPION, due to the scandal generated by DENGVAXIA, where 14 deaths were reported by the vaccine and they also report that they were not duly informed of the pro and contras of the DENGUE vaccine.
"... the parents used to go alone when there were vaccination campaigns ... now we have to go and get them and convince them to vaccinate their children ..." said a source from the health department in the PHILIPPINES.
This shows you in a CLEAR and CRYSTAL way of how a VACCINE that is invented to prevent a disease, can NEGATIVELY affect society in their perception of them, when it generates PROBLEMS in terms of results: DENGVAXIA is another example rather than adds to those already mentioned in other articles CERVARIX AND GARDASIL against HPV and LYMErix against LYME DISEASE.
Do you want my opinion about it? I'll give it to you as always:
CONCLUSIONS:
1.) THE LABORATORY knew of the potential problem of the vaccine and only until I ordered a second analysis of the DATA, I accept the harsh reality of it, after thousands of children had already been vaccinated.
2.) THE VACCINE WAS DEVELOPED FROM THE YELLOW FEVER VIRUS, the new vaccines to come are being developed from particles of the DENGUE VIRUS.
3.) Like other VACCINES, DENGVAXIA, caused changes in the immunity of the vaccinated SERONEGATIVE, making them more susceptible to a MORE SEVERE DENGUEin case of exposure.
4.) THE FAILURE of the same in the PHILIPPINES caused panic in the population "scaring" patients, parents and teachers to receive other vaccines which caused a MORTAL SARAMPION OUTBREAK.
5.) As a final data, I close this review by telling all the countries that they "PURCHASED" THE VACCINE that takes into account what is stated here, to avoid collateral damage.
If you are a "BELIEVER" OR "NOT BELIEVER" of the vaccines, I recommend that you read the BIBLIOGRAPHIC REFERENCES, and draw your conclusions.
"... Only by creating trust can you obtain a positive response from the population, if you hide or manipulate the truth, sooner or later you will be billed ..."
Greetings to all.
Dr. José Lapenta. Dermatologist
=================
Hello friends of the network DERMAGIC EXPRESS brings you another impressive topic that has to do once more with the VACCINES: it is the SCANDAL IN THE PHILIPPINES FOR THE DENGVAXIA VACCINE AGAINST THE DENGUE. A relatively new vaccine on the market that was approved by the FDA in the year 2015 to combat this plague "DENGUE" and the first country to put it into practice was the PHILIPPINES, although it was also approved in other countries.
THE DENGUE virus is transmitted by mosquito Aedes Aegypus, Aedes Albopictus, Aedes. Polynesiensis and Aedes scutellaris. The virus crosses the placenta, but is not associated with birth defects, it is also transmitted by blood transfusions and organ transplants. Until the year 2.015 there was no vaccine against this plague spread throughout much of the planet until the DENGVAXIA VACCINE was approved, manufactured by the French Sanofi-Pasteur laboratory, developed in (Lyon).
Today I brought this topic which is a clear demonstration of why the population day after day REJECTS MORE AND MORE VACCINES, it is not about advertising campaigns, neither "VAXERS" or "ANTIVAXERS" as society calls them. These are scientific and clinically proven events that show the failure of THE LABORATORIES in this case SANOFI-PASTEUR, who recognized in the year 2.016, months after the release of the DENGVAXIA VACCINE, the collateral damage of the same, after having been placed in 800,000 school children in the PHILIPPINES AND 300,000, in BRAZIL.
The DENGUE VIRUS (DENV) as I told you is transmitted by the bite of the aforementioned mosquitoes, it is a virus TYPE: RNA virus, from the FAMILY: Flaviviridae; GENUS: Flavivirus; SPECIES: Dengue viruses, of which there are 5 serotypes. Classically, we talked about 4 serotypes, but later a 5th serotype was described. Each of these is capable of manifesting the entire spectrum of the disease.
Some scientists argue that some are more virulent than others, popularly speaking of a CLASSIC DENGUE, which has no HEMORRHAGIC manifestations, or mild and a HEMORRHAGIC DENGUE, with severe manifestations of bleeding that can cause the death of the patient.
Dengue is the most widespread mosquitoes-transmitted disease in the world, with almost 400 million people infected each year. There are four dengue viruses, or serotypes, (there is a 5th serotype), most infected people recover and become immune to the first serotype they had. In some cases, a subsequent infection with a different serotype can cause severe hemorrhagic fever, called HEMORRHAGIC DENGUE, which is estimated to cause 25,000 deaths each year.
This is what led the LABORATORIES to develop VACCINES against this plague, not only SANOFI-PASTEUR, there are other THREE (3) VACCINES on trial, of which I will not mention anything at the moment because they have not been approved by the FDA yet.
DENGVAXIA is a vaccine called chimeric tetravalent yellow fever vaccine (CYD-TYD), composed of 4 chimeras YELLOW FEVER virus (17D-DENV) which is capable of causing the development of antibodies against the DENGUE virus (DENGV), and protects against the 4 most common serotypes of dengue. In this principle the creation of this VACCINE was based, which according to the same laboratory was 10 years developing. The vaccine is administered in 3 doses.
In summary DENGVAXIA is produced from the YELLOW FEVER virus genetically designed to produce stimulation of the immune system to produce antibodies against the DENGUE virus.
The "scandal" began to uncover in February 2,106 after the PHILIPPINES vaccination program was already under way and a doctor (DR Halstead) warned in a scientific article that the vaccine could put people at risk if they had not had dengue previously. He said that "the problem was well known." This researcher and others pointed out that in a DENGVAXIA study published in 2.015 it seemed to CONFIRM the fears that the vaccine could be harmful for those who had no previous EXPOSURE to dengue, noting that the potential danger was in the immune response to the VACCINE. It was found that children under 9 years of age who had received DENGVAXIA and subsequently were infected with DENGUE were more likely to be HOSPITALIZED due to serious diseases than those who had not been vaccinated.
To summarize: healthy children vaccinated with DENGVAXIA, that is to say seronegative, are more prone to develop a MORE SEVERE DENGUE and OTHER DISEASES than children NOT vaccinated with DENGVAXIA (seronegative also) and who were then acquired DENGUE.
The finding originally led Sanofi to restrict Dengvaxia to children 9 years old and older; In BRAZIL, the government decided to limit this vaccination program to children over 15 years of age. And the World Health Organization (WHO) in 2.017 recommended only using the vaccine in places where the incidence of DENGUE is high.
The vaccine was approved for use in 2,016 as "PARTIALLY" EFFECTIVE "in 11 countries: Mexico, the Philippines, Indonesia, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Thailand and Singapore ... The scandal erupted in the PHILIPPINES where 800,000 thousand school children were vaccinated regardless of their serological status, which is the high point of this vaccine.The SEROLOGICAL STATUS of the vaccinated and not THE AGE.
When the problem came to "light", the Philippine Food and Drug Administration ordered Sanofi to stop its campaign and in October 2016 fined Sanofi and Watson, a pharmacy chain that had started its own promotion campaign, for violating the advertising laws.
On November 29, 2017 SANOFI decided to "UPDATE" the information provided to doctors and patients about the DENGVAXIA VACCINATION and its performance, based on the request made by the countries that acquired it and affirm that it provides protection against dengue, but As I told you previously, they AFFIRMED THAT CERTAINLY and quote:
"... Those who had not been previously infected with the dengue virus (seronegative), the analysis found that in the longer term, more cases of severe disease could occur after vaccination after a dengue infection .."
This fact "ignited" the alarms and there were social demonstrations in front of the PHILIPPINES 'Parliament and two (2) days later on DECEMBER 1, 2017, 2 and a half months ago - the Philippines suspends the immunization program against dengue after the French pharmaceutical giant Sanofi warned that its flagship vaccine, DENGVAXIA, had shown that it presented health risks in people who had not been previously infected.
By the time of the suspension, more than 740,000 schoo lchildren had been vaccinated with DENGVAXIA, without taking into account the serological status of the children and the panel that proposed the suspension expressed its concern about the "REVELATION" of Sanofi regarding the problem of its vaccine.
To close this case we can mention that a few days ago March 8, 2,018 the PHILIPPINES health department warns of an outbreak of MORTAL MEASLESL, as a sequel to the problem caused by DENGVAXIA, relatives, parents and teachers refuse to VACCINATE their children with proven vaccines such as the SARAMPION, due to the scandal generated by DENGVAXIA, where 14 deaths were reported by the vaccine and they also report that they were not duly informed of the pro and contras of the DENGUE vaccine.
"... the parents used to go alone when there were vaccination campaigns ... now we have to go and get them and convince them to vaccinate their children ..." said a source from the health department in the PHILIPPINES.
This shows you in a CLEAR and CRYSTAL way of how a VACCINE that is invented to prevent a disease, can NEGATIVELY affect society in their perception of them, when it generates PROBLEMS in terms of results: DENGVAXIA is another example rather than adds to those already mentioned in other articles CERVARIX AND GARDASIL against HPV and LYMErix against LYME DISEASE.
Do you want my opinion about it? I'll give it to you as always:
CONCLUSIONS:
1.) THE LABORATORY knew of the potential problem of the vaccine and only until I ordered a second analysis of the DATA, I accept the harsh reality of it, after thousands of children had already been vaccinated.
2.) THE VACCINE WAS DEVELOPED FROM THE YELLOW FEVER VIRUS, the new vaccines to come are being developed from particles of the DENGUE VIRUS.
3.) Like other VACCINES, DENGVAXIA, caused changes in the immunity of the vaccinated SERONEGATIVE, making them more susceptible to a MORE SEVERE DENGUEin case of exposure.
4.) THE FAILURE of the same in the PHILIPPINES caused panic in the population "scaring" patients, parents and teachers to receive other vaccines which caused a MORTAL SARAMPION OUTBREAK.
5.) As a final data, I close this review by telling all the countries that they "PURCHASED" THE VACCINE that takes into account what is stated here, to avoid collateral damage.
If you are a "BELIEVER" OR "NOT BELIEVER" of the vaccines, I recommend that you read the BIBLIOGRAPHIC REFERENCES, and draw your conclusions.
"... Only by creating trust can you obtain a positive response from the population, if you hide or manipulate the truth, sooner or later you will be billed ..."
Greetings to all.
Dr. José Lapenta. Dermatologist
Dr. José Miguel Lapenta. MD.
EDITORIAL ESPAÑOL:
===================
Hola amigos de la red DERMAGIC EXPRESS te trae otro tema impactante y que tiene que ver una vez más con las VACUNAS: se trata del ESCANDALO EN FILIPINAS POR LA VACUNA DENGVAXIA CONTRA EL DENGUE. Vacuna relativamente nueva en el mercado y que fue aprobada por la FDA en él año 2.015 para combatir esta peste "DENGUE" y el primer país en ponerla en práctica fue FILIPINAS, aunque fue aprobada también en otros países.
EL DENGUE virus es transmitido por mosquito Aedes Aegypus, Aedes Albopictus, Aedes. Polynesiensis y Aedes scutellaris. El virus atraviesa la placenta, pero no está asociado con defectos al nacer, también se transmite por transfusiones sanguíneas y trasplante de órganos. Hasta el año 2.015 no existía vacuna contra esta plaga diseminada en gran parte del planeta hasta que se aprobó la VACUNA DENGVAXIA del laboratorio Francés Sanofi- Pasteur, desarrollada en (Lyon)
Hoy les traje este tema el cual es una clara demostración el porque la población día a día RECHAZA MAS Y MAS LAS VACUNAS, no se trata de campañas publicitarias, ni de VAXERS o ANTIVAXERS como los llama la sociedad. Se trata de eventos científicos y clínicamente demostrados que evidencian el fallo de LOS LABORATORIOS en este caso SANOFI-PASTEUR, quien reconoció en el año 2.016, meses después de liberada la VACUNA DENGVAXIA, los daños colaterales de la misma, luego de haber sido colocada en 800.000 mil escolares en FILIPINAS Y 300.000 mil EN BRASIL.
El DENGUE VIRUS (DENV) como ya les dije es transmitido por la picadura de los mosquitos ya mencionados, es un virus TIPO: ARN virus, de la FAMILIA: Flaviviridae; GENUS: Flavivirus; ESPECIES: Dengue virus, de los cuales existen 5 serotipos. Clásicamente se hablo de 4 serotipos, pero posteriormente fue descrito un 5to serotipo. Cada uno de estos es capaz de manifestar todo el espectro de la enfermedad.
Algunos científicos sostienen que algunos son más virulentos que otros, hablándose popularmente de un DENGUE CLASICO, el cual no tiene manifestaciones HEMORRAGICAS, o leve y un DENGUE HEMORRAGICO, con manifestaciones severas de sangrado que pueden ocasionar la muerte del paciente.
El dengue es la enfermedad transmitida por moquitos más extendida en el mundo, con casi 400 millones de personas infectadas cada año. Hay cuatro virus del dengue, o serotipos, (hay un 5to serotipo), la mayoría de las personas infectadas se recuperan y se vuelven inmunes al primer serotipo que tenían. En algunos casos, una infección posterior con un serotipo diferente puede provocar una fiebre hemorrágica grave, denominada DENGUE HEMORRAGICO el cual Se estima provoca 25.000 muertes cada año.
===================
Hola amigos de la red DERMAGIC EXPRESS te trae otro tema impactante y que tiene que ver una vez más con las VACUNAS: se trata del ESCANDALO EN FILIPINAS POR LA VACUNA DENGVAXIA CONTRA EL DENGUE. Vacuna relativamente nueva en el mercado y que fue aprobada por la FDA en él año 2.015 para combatir esta peste "DENGUE" y el primer país en ponerla en práctica fue FILIPINAS, aunque fue aprobada también en otros países.
EL DENGUE virus es transmitido por mosquito Aedes Aegypus, Aedes Albopictus, Aedes. Polynesiensis y Aedes scutellaris. El virus atraviesa la placenta, pero no está asociado con defectos al nacer, también se transmite por transfusiones sanguíneas y trasplante de órganos. Hasta el año 2.015 no existía vacuna contra esta plaga diseminada en gran parte del planeta hasta que se aprobó la VACUNA DENGVAXIA del laboratorio Francés Sanofi- Pasteur, desarrollada en (Lyon)
Hoy les traje este tema el cual es una clara demostración el porque la población día a día RECHAZA MAS Y MAS LAS VACUNAS, no se trata de campañas publicitarias, ni de VAXERS o ANTIVAXERS como los llama la sociedad. Se trata de eventos científicos y clínicamente demostrados que evidencian el fallo de LOS LABORATORIOS en este caso SANOFI-PASTEUR, quien reconoció en el año 2.016, meses después de liberada la VACUNA DENGVAXIA, los daños colaterales de la misma, luego de haber sido colocada en 800.000 mil escolares en FILIPINAS Y 300.000 mil EN BRASIL.
El DENGUE VIRUS (DENV) como ya les dije es transmitido por la picadura de los mosquitos ya mencionados, es un virus TIPO: ARN virus, de la FAMILIA: Flaviviridae; GENUS: Flavivirus; ESPECIES: Dengue virus, de los cuales existen 5 serotipos. Clásicamente se hablo de 4 serotipos, pero posteriormente fue descrito un 5to serotipo. Cada uno de estos es capaz de manifestar todo el espectro de la enfermedad.
Algunos científicos sostienen que algunos son más virulentos que otros, hablándose popularmente de un DENGUE CLASICO, el cual no tiene manifestaciones HEMORRAGICAS, o leve y un DENGUE HEMORRAGICO, con manifestaciones severas de sangrado que pueden ocasionar la muerte del paciente.
El dengue es la enfermedad transmitida por moquitos más extendida en el mundo, con casi 400 millones de personas infectadas cada año. Hay cuatro virus del dengue, o serotipos, (hay un 5to serotipo), la mayoría de las personas infectadas se recuperan y se vuelven inmunes al primer serotipo que tenían. En algunos casos, una infección posterior con un serotipo diferente puede provocar una fiebre hemorrágica grave, denominada DENGUE HEMORRAGICO el cual Se estima provoca 25.000 muertes cada año.
Esto fue lo que llevo a los LABORATORIOS A desarrollar VACUNAS contra esta plaga, no solo SANOFI-PASTEUR, por allí están en ensayo otras TRES (3) VACUNAS, de las cuales no voy a mencionar nada por los momentos debido a que no han sido aprobadas por la FDA todavía.
DENGVAXIA es una vacuna que se denomina: vacuna tetravalente quimérica de la fiebre amarilla (CYD-TYD), compuesta por 4 quimeras del virus de la FIEBRE AMARILLA (17D-DENV) la cual es capaz de provocar el desarrollo de anticuerpos contra el virus del DENGUE (DENGV), y protege contra los 4 serotipos más comunes del dengue. En este principio se baso la creación de esta VACUNA, que según el mismo laboratorio estuvo 10 años desarrollándose. La vacuna se administra en 3 dosis.
En resumen DENGVAXIA es producida a partir del virus DE LA FIEBRE AMARILLA diseñado genéticamente para producir estimulación del sistema inmune a producir anticuerpos contra el virus del DENGUE.
El escándalo comenzó a destaparse en Febrero de 2.106 luego de que el programa de vacunación en FILIPINAS ya estaba en marcha y un medico (DR. Halstead) advirtió en un artículo científico que la vacuna podría poner a las personas en riesgo si no hubieran tenido dengue previamente. Dijo que "el problema era bien conocido". Este investigador y otros señalaron que en un estudio de DENGVAXIA publicado en 2.015 parecía CONFIRMAR los temores que la vacuna podría se dañina para aquellos que no tenían EXPOSICION previa al dengue, señalando que el peligro potencial estaba en la respuesta inmune a la VACUNA. Encontrándose que los niños menores de 9 años que habían recibido DENGVAXIA y posteriormente se contagiaron de DENGUE eran más propensos a ser HOSPITALIZADOS por enfermedades graves que aquellos que no habían sido vacunados.
Para resumírtelo: niños sanos vacunados con DENGVAXIA, es decir seronegativos, están mas propensos a desarrollar un DENGUE MAS SEVERO y OTRAS ENFERMEDADES que los niños NO VACUNADOS con DENGVAXIA (seronegativos también) y que luego fueron adquirieron DENGUE.
El hallazgo llevó originalmente a Sanofi a restringir Dengvaxia a niños de 9 años o más; en BRASIL el gobierno decidió limitar este programa de vacunación a niños mayores de 15 años. Y la Organización Mundial de La salud (OMS) en 2.017 recomendó solo usar la vacuna en sitios donde la incidencia del DENGUE es alta.
La vacuna fue aprobada para su uso en 2.016 como "PARCIALMENTE" EFECTIVA" en 11 países: México, Filipinas, Indonesia, Brasil, El Salvador, Costa Rica, Paraguay, Guatemala, Perú, Tailandia y Singapur...El escándalo estallo en FILIPINAS donde se vacunaron 800.000 mil niños escolares independientemente de su estado serológico, el cual es el punto álgido de esta vacuna. El ESTADO SEROLOGICO de los vacunados y no LA EDAD.
Cuando sale a la luz pública el problema, la Administración de Drogas y Alimentos de Filipinas ordenó a Sanofi detener su campaña y en octubre de 2.016 multó a Sanofi y Watson, una cadena de farmacias que había comenzado su propia campaña de promoción, por violar las leyes de publicidad.
El 29 de Noviembre de 2.017 SANOFI decide "ACTUALIZAR" la información suministrada a médicos y pacientes sobre la VACUNA DENGVAXIA y su rendimiento, en base a la solicitud hecha por los países que la adquirieron y afirman que la misma proporciona protección contra el dengue, pero como les dije previamente AFIRMARON QUE CIERTAMENTE y cito textualmente:
" ...Aquellos que no habían sido infectados previamente por el virus del dengue (seronegativos), el análisis encontró que a más largo plazo, más casos de enfermedad severa podrían ocurrir luego de la vacunación luego de una infección por dengue.. "
" ...Aquellos que no habían sido infectados previamente por el virus del dengue (seronegativos), el análisis encontró que a más largo plazo, más casos de enfermedad severa podrían ocurrir luego de la vacunación luego de una infección por dengue.. "
Este hecho "encendió" las alarmas y hubo manifestaciones sociales frente al Parlamento de FILIPINAS y dos (2) días después el 1 DE DICIEMBRE DE 2.107, hace 2 meses y medio apenas - Filipinas suspende el programa de inmunización contra el dengue luego de que el gigante farmacéutico francés Sanofi advirtiera que su vacuna insignia, DENGVAXIA, había demostrado que presentaba riesgos para la salud en personas que no habían sido infectadas previamente.
Para el momento de la suspensión mas 740.000 mil escolares habían sido vacunados con DENGVAXIA, sin tomar en cuenta el estado serológico de los niños y el panel que propuso la suspensión manifestó su preocupación por la "REVELACION" de Sanofi con respecto al problema de su vacuna.
Para cerrar este caso podemos citar que hace pocos días 8 de Marzo 2.018 el departamento de Salud de FILIPINAS alerta sobre un brote de MORTAL de Sarampión, como secuela del problema que ocasiono DENGVAXIA, los familiares, padres y maestros se niegan a VACUNAR a sus hijos con vacunas ya probadas como la del SARAMPION, por el escándalo que genero DENGVAXIA, donde se reportaron 14 muertes por la vacuna y además refieren que no fueron informados debidamente de los pro y contra de la vacuna contra el DENGUE.
"... los padres antes acudían solos cuando había campamás de vacunación...ahora tenemos que ir a buscarlos y convencerlos para que vacunen a sus hijos..." cito una fuente del departamento de salud en FILIPINAS.
Esto te demuestra DE UNA MANERA CLARA y CRISTALINA de como una vacuna que se inventa para prevenir una enfermedad, puede afectar NEGATIVAMENTE a la sociedad en su percepción sobre las mismas, cuando la misma genera PROBLEMAS en cuanto a resultados: DENGVAXIA es otro ejemplo más que se suma a las ya mencionadas en otros artículos CERVARIX Y GARDASIL contra el VPH y LYMErix contra LA ENFERMEDAD DE LYME.
Quieres mi opinión al respecto? te la voy a dar como siempre:
CONCLUSIONES:
1.) EL LABORATORIO sabia de el potencial problema de la vacuna y solo hasta que ordeno un segundo análisis de la DATA, acepto la cruda realidad de la misma, después que ya se habían vacunado miles de niños.
2.) LA VACUNA FUE DESARROLLADA a partir DEL VIRUS DE LA FIEBRE AMARILLA, las nuevas vacunas por venir están siendo desarrolladas a partir de partículas del VIRUS DEL DENGUE.
3.) Como otras VACUNAS, DENGVAXIA, provoco cambios en la inmunidad de los vacunados SERONEGATIVOS, haciéndolos mas susceptibles a un DENGUE MAS SEVERO en caso de exposición.
4.) EL FRACASO de la misma en FILIPINAS provoco pánico en la población "asustando" a los pacientes, padres y maestros a recibir otras vacunas lo que provoco un BROTE MORTAL DE SARAMPION.
5.) Como dato final cierro esta revisión diciéndole a todos los países que "COMPRARON" LA VACUNA que tomen en cuenta lo que aquí se expone, para evitar daños colaterales.
Si eres un "CREEDOR" O "NO CREEDOR" de las vacunas te recomiendo que leas las REFERENCIAS BIBLIOGRAFICAS, y saques tus conclusiones.
Si eres un "CREEDOR" O "NO CREEDOR" de las vacunas te recomiendo que leas las REFERENCIAS BIBLIOGRAFICAS, y saques tus conclusiones.
" ... Solo creando confianza puedes obtener de la población una respuesta positiva, si escondes o manipulas la verdad, tarde o temprano te pasara factura..."
Saludos a todos.
Dr. José Lapenta. Dermatologist
Dr. José Miguel Lapenta. MD.
================================================================
BIBLIOGRAPHICAL REFRERENCES / REFERENCIAS BIBLIOGRAFICAS
=================================================================
1.) Drug Company Under Fire After Revealing Dengue Vaccine May Harm Some
By DENISE GRADY and KATIE THOMASDEC. 17, 2017 Source: https://www.nytimes.com/2017/12/17/health/sanofi-dengue-vaccine-philippines.html
====================================================
2.) Dengue vaccine: WHO position paper – July 2016 source: http://www.who.int/wer/2016/wer9130.pdf?ua=1
====================================================
3.) Sanofi updates information on dengue vaccine. New analysis of long-term Dengvaxia®
Data found differences in vaccine performance based on prior dengue infection Company will ask regulators to update product label to reflect new information.
=====================================================
4.) Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine. 2016 Mar 29;34(14):1643-7. doi: 10.1016/j.vaccine.2016.02.004. Epub 2016 Feb 10.[PUBMED] Authors: Scott B.HalsteadaPhilip K.Russellb
====================================================
5.) Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. Sri Rezeki Hadinegoro, M.D., Ph.D., Jose Luis Arredondo-García, M.D., Maria Rosario Capeding, M.D., Carmen Deseda, M.D., Tawee Chotpitayasunondh, M.D., Reynaldo Dietze, M.D., H.I. Hj Muhammad Ismail, M.B., B.S., Humberto Reynales, M.D., Ph.D., Kriengsak Limkittikul, M.D., Doris Maribel Rivera-Medina, M.D., Huu Ngoc Tran, M.D., Ph.D., Alain Bouckenooghe, M.D., Danaya Chansinghakul, M.D., Margarita Cortés, M.D., Karen Fanouillere, M.Sc., M.P.H., Remi Forrat, M.D., Carina Frago, M.D., Sophia Gailhardou, Pharm.D., Nicholas Jackson, Ph.D., Fernando Noriega, M.D., Eric Plennevaux, Ph.D., T. Anh Wartel, M.D., Betzana Zambrano, M.D., and Melanie Saville, M.B., B.S.
for the CYD-TDV Dengue Vaccine Working Group*
=============================================================
5.) Philippines Suspends Dengue Shots After Drug Firm’s Warning
By FELIPE VILLAMORDEC. 1, 2017. The New York times. Source: https://www.nytimes.com/2017/12/01/world/asia/philippines-dengue-vaccine.html?action=click&contentCollection=Health&module=RelatedCoverage®ion=Marginalia&pgtype=article
==============================================================
6.) First Dengue Fever Vaccine Approved by Mexico
By ANDREW POLLACKDEC. 9, 2015. The New York Times Source: https://www.nytimes.com/2015/12/10/business/first-dengue-fever-vaccine-approved-by-mexico.html?action=click&contentCollection=Asia%20Pacific&module=RelatedCoverage®ion=Marginalia&pgtype=article
==============================================================
7.) Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine. Hum Vaccin Immunother. 2018 Feb 26:0. doi: 10.1080/21645515.2018.1445448. [Epub ahead of print] [PUBMED]. Halstead SB1.
========================================================
8.) Consider stopping dengvaxia administration without immunological screening. Expert Rev Vaccines. 2017 Apr;16(4):301-302. doi: 10.1080/14760584.2017.1276831. Epub 2016 Dec 28. [PUBMED] Aguiar M1, Halstead SB2, Stollenwerk N1.
========================================================
9.) Dengue vaccines: Are they safe for travelers? Travel Med Infect Dis. 2016 Jul-Aug;14(4):378-83. doi: 10.1016/j.tmaid.2016.06.005. Epub 2016 Jun 22. [PUBMED]. Halstead SB1, Aguiar M2.
=======================================================
10.) Dengvaxia: age as surrogate for serostatus, Maíra AguiarEmail the author Maíra Aguiar, Nico Stollenwerk. Published: 21 December 2017.PlumX Metrics. Source:
=======================================================================
11.) WHO Strategic Advisory Group of Experts on Immunization. Background paper on dengue vaccines. Prepared by the SAGE working group on dengue vaccines and the WHO secretariat. ((accessed April 16, 2016).) Source:
http://www.who.int/immunization/sage/meetings/2016/april/1_Background_Paper_Dengue_Vaccines_2016_03_17.pdf?ua=1 Date: March 17, 2016
=====================================================================
12.) The risks behind Dengvaxia recommendation. Lancet Infect Dis. 2016; 16: 882–883.
Aguiar, M, Stollenwerk, N, and Halstead, SB.
====================================================================
13.) Consider stopping Dengvaxia administration without immunological screening. Expert Rev Vaccines. 2017; 16: 301–302. Aguiar, M, Halstead, SB, and Stollenwerk, N.
=============================================================
14.) The impact of the newly licensed dengue vaccine in endemic countries. PLoS Negl Trop Dis. 2016; 10: e0005179. Aguiar, M, Stollenwerk, N, and Halstead, SB.
=============================================================
15.) Sanofi. Sanofi updates information on dengue vaccine. ((accessed Nov 29, 2017).)
Date: Nov 29, 2017
============================================================
16.) WHO. WHO advises Dengvaxia be used only in people previously infected with dengue. ((accessed Dec 14, 2017).)
http://www.who.int/medicines/news/2017/WHO-advises-dengvaxia-used-only-in-people-previously-infected/en/ Date: Dec 13, 2017
============================================================
17.) Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine. Clin Infect Dis. 2018 Jan 6;66(2):178-184. doi: 10.1093/cid/cix766. [PUBMED] Yang Y1, Meng Y1, Halloran ME2,3, Longini IM Jr1.
============================================================
18.) Dengvaxia Efficacy Dependency on Serostatus: A Closer Look at More Recent Data
Maíra Aguiar Nico Stollenwerk
Clinical Infectious Diseases, Volume 66, Issue 4, 1 February 2018, Pages 641–642, https://doi.org/10.1093/cid/cix882 Published: 21 October 2017. Source:
============================================================
19.) Deadly measles outbreak as Philippines reels from vaccine row. THE STRAITSTIMES/ ASIA. Source: http://www.straitstimes.com/asia/se-asia/deadly-measles-outbreak-as-philippines-reels-from-vaccine-row
============================================================
20.) Dengue Fever Vaccine Available in Indonesia Monday, 17 October, 2016 | 14:10 WIB
Source: https://en.tempo.co/read/news/2016/10/17/310812742/Dengue-Fever-Vaccine-Available-in-Indonesia
=============================================================
21.) Caution on new dengue vaccine: In some countries, harm outweighs benefit
By Helen Branswell @HelenBranswell. September 1, 2016
=============================================================
22.) Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits. PLoS Med. 2016 Nov 29;13(11):e1002182. doi: 10.1371/journal.pmed.1002182. eCollection 2016 Nov. [PUBMED]Deen J1.=============================================================
23.) [Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico's Universal Vaccination Program].
[Article in Spanish] Salud Publica Mex. 2016 Jan-Feb;58(1):71-83. [PUBMED.Hernández-Ávila M1, Lazcano-Ponce E1, Hernández-Ávila JE1, Alpuche-Aranda CM1, Rodríguez-López MH1, García-García L1, Madrid-Marina V1, López Gatell-Ramírez H1, Lanz-Mendoza H1, Martínez-Barnetche J1, Díaz-Ortega JL1, Ángeles-Llerenas A1, Barrientos-Gutiérrez T1, Bautista-Arredondo S1, Santos-Preciado JI2.
==============================================================
24.) Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward. Vaccine. 2015 Dec 10;33(50):7100-11. doi: 10.1016/j.vaccine.2015.09.108. Epub 2015 Oct 20. [PUBMED]. Guy B1, Briand O2, Lang J3, Saville M3, Jackson N3.
No hay comentarios:
Publicar un comentario
Tu comentario será objeto de revisión y luego aprobado.
Your comment will be revised and then approved.